Table 4.
This table summarizes the logistic-regression results of the effect of exposure to organic Hg in Thimerosal-preserved hepatitis B vaccines, used within the first six months after birth, for female cases with a premature puberty diagnosis compared to the female controls 1.
| Group Examined (ICD-9 Code) | Reference Dose 0 µg Hg (%) | 12.5 µg Hg (%) | 25 µg Hg (%) | 37.5 µg Hg (%) | Odds Ratio Per µg Hg (95% CI) [p-Value] |
|---|---|---|---|---|---|
| Female Premature Puberty Cases (259.1) | 12 (2.62) | 2 (0.44) | 391 (85.37) | 53 (11.57) | |
| 1.0281 (1.0104–1.0462) [<0.005] | |||||
| Female Controls | 932 (3.57) | 356 (1.36) | 22,896 (87.66) | 1935 (7.41) |
1 The control subjects were enrolled continuously from their birth, for a minimum of 5.59 years (the mean age of their initial premature puberty diagnosis plus the SD of mean age of their initial premature puberty diagnosis). Hg = mercury, µg = microgram, SD = standard deviation.